Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 3/20 | 0.31 |
| ▸ | EGFR | P00533 | 2/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | XBP1 | P17861 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.31 |
| ▸ | GLP1R | P43220 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1159252 | 0.79 | NOS3 (0.33) | RAB9AALDH1A1NPC1MAPTMAPK1 | |
| SCHEMBL549184 | 0.79 | CYP1A2 (0.47) | RAB9ALMNANOTUMALDH1A1NPC1 | |
| SCHEMBL31543156 | 0.76 | ALDH1A1 (0.35) | DGAT1RAB9AALDH1A1NPC1TP53 | |
| SCHEMBL1767872 | 0.74 | IRAK4 (0.30) | — | |
| SCHEMBL3302582 | 0.74 | DGAT1 (0.44) | DGAT1RAB9AALDH1A1NPC1TP53 | |
| SCHEMBL26870603 | 0.72 | KMT2A (0.38) | DGAT1RAB9ALMNAALDH1A1MAPT | |
| SCHEMBL31675887 | 0.72 | ALDH1A1 (0.34) | DGAT1RAB9ALMNAEGFRNOTUM | |
| SCHEMBL23219333 | 0.71 | DGAT1 (0.49) | DGAT1RAB9AALDH1A1NPC1TP53 | |
| SCHEMBL29832003 | 0.71 | GALR3 (0.35) | DGAT1RAB9ALMNAALDH1A1NPC1 | |
| SCHEMBL28855943 | 0.71 | GALR3 (0.35) | DGAT1RAB9ALMNAALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391795-A1 | MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-12-07 | — | — | US | disclosed |
| EP-4236938-A1 | MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-09-06 | — | — | EP | disclosed |
| CN-116600803-A | Macrocyclic urea orexin receptor agonists | 默沙东有限责任公司 | 2023-08-15 | — | — | CN | disclosed |
| WO-2022094012-A1 | MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022094012-A1 | MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-05-05 | — | — | WO | disclosed |
| US-20150005321-A1 | Indole and azaindole modulators of the alpha 7 nAChR | PROXIMAGEN LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
| US-20150005321-A1 | Indole and azaindole modulators of the alpha 7 nAChR | PROXIMAGEN LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
| US-20150005321-A1 | Indole and azaindole modulators of the alpha 7 nAChR | PROXIMAGEN LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
| US-8796283-B2 | Indole and azaindole modulators of the alpha 7 nachr | PROXIMAGEN LIMITED (GB) | 2014-08-05 | — | — | US | disclosed |
| US-8796283-B2 | Indole and azaindole modulators of the alpha 7 nachr | PROXIMAGEN LIMITED (GB) | 2014-08-05 | — | — | US | disclosed |
| US-20120283242-A1 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-11-08 | — | — | US | disclosed |
| US-20120283273-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | PROXIMAGEN LIMITED (UK) | 2012-11-08 | — | — | US | disclosed |
| US-20120283273-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | PROXIMAGEN LIMITED (UK) | 2012-11-08 | — | — | US | disclosed |
| US-20120283273-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | PROXIMAGEN LIMITED (UK) | 2012-11-08 | — | — | US | disclosed |
| EP-2488514-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | Proximagen Limited (GB) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011045353-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | PROXIMAGEN LIMITED (GB) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011045353-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | PROXIMAGEN LIMITED (GB) | 2011-04-21 | — | — | WO | disclosed |
| EP-1572693-A1 | MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS | Pharmacia Corporation (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20040209897-A1 | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds | PHARMACIA CORPORATION | 2004-10-21 | — | — | US | disclosed |
| WO-2004058762-A1 | MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005321-A1 | Indole and azaindole modulators of the alpha 7 nAChR | CHRNA7, CHRNA5, CHRNA1 | DGAT1 3051/4885RAB9A 1193/4885LMNA 3803/4885 |
| US-20120283273-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | CHRNA7, CHRNA5, CHRNA1 | DGAT1 2925/4885RAB9A 1156/4885LMNA 3819/4885 |
| US-20040209897-A1 | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds | MAPKAPK2, MAP3K2, MKNK2 | DGAT1 2464/4885RAB9A 2001/4885LMNA 3207/4885 |
| US-20230391795-A1 | MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, CRHR1 | DGAT1 3125/4885RAB9A 2881/4885LMNA 3669/4885 |
| US-20120283242-A1 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | TPD52L2, CCNE2, CDK2 | DGAT1 2188/4885RAB9A 3204/4885LMNA 2547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.